A new vitamin K epoxide reductase complex subunit-1 (VKORC1) mutation in a patient with decreased stability of CYP2C9 enzyme

被引：31

作者：

D'Ambrosio, R. L.

D'Andrea, G.

Cafolla, A.

Faillace, F.

Margaglione, M.

机构：

[1] Univ Roma La Sapienza, Dept Haematol, Rome, Italy

[2] IRCCS Casa Sollievo della Soerenza, Unita Aterosclerosi & Trombosi, Rome, Italy

[3] Univ Studi Foggia, Dipartimento Sci Biomed, Cattedra Genet Med, I-71100 Foggia, Italy

来源：

JOURNAL OF THROMBOSIS AND HAEMOSTASIS | 2007年 / 5卷 / 01期

关键词：

D O I：

10.1111/j.1538-7836.2006.02261.x

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：191 / 193

页数：4

共 8 条

[1] Discovery of new potentially defective alleles of human CYP2C9
Blaisdell, J
Jorge-Nebert, LF
Coulter, S
Ferguson, SS
Lee, SJ
Chanas, B
Xi, T
Mohrenweiser, H
Ghanayem, B
Goldstein, JA
[J]. PHARMACOGENETICS, 2004, 14 (08): : 527 - 537
[2] A vitamin K epoxide reductase complex subunit-1 (VKORC1) mutation in a patient with vitamin K antagonist resistance
Bodin, L
Horellou, MH
Flaujac, C
Loriot, MA
Samama, MM
[J]. JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2005, 3 (07) : 1533 - 1535
[3] A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin
D'Andrea, G
D'Ambrosio, RL
Di Perna, P
Chetta, M
Santacroce, R
Brancaccio, V
Grandone, E
Margaglione, M
[J]. BLOOD, 2005, 105 (02) : 645 - 649
[4] Vitamin K epoxide reductase: homology, active site and catalytic mechanism
Goodstadt, L
Ponting, CP
[J]. TRENDS IN BIOCHEMICAL SCIENCES, 2004, 29 (06) : 289 - 292
[5] Pharmacodynamic resistance to warfarin associated with a Val66Met substitution in vitamin K epoxide reductase complex subunit I
Harrington, DJ
Underwood, S
Morse, C
Shearer, MJ
Tuddenham, EGD
Mumford, AD
[J]. THROMBOSIS AND HAEMOSTASIS, 2005, 93 (01) : 23 - 26
[6] IMPAIRED (S)-WARFARIN METABOLISM CATALYZED BY THE R144C ALLELIC VARIANT OF CYP2C9
RETTIE, AE
WIENKERS, LC
GONZALEZ, FJ
TRAGER, WF
KORZEKWA, KR
[J]. PHARMACOGENETICS, 1994, 4 (01): : 39 - 42
[7] Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2
Rost, S
Fregin, A
Ivaskevicius, V
Conzelmann, E
Hörtnagel, K
Pelz, HJ
Lappegard, K
Seifried, E
Scharrer, I
Tuddenham, EGD
Müller, CR
Strom, TM
Oldenburg, J
[J]. NATURE, 2004, 427 (6974) : 537 - 541
[8] In-vitro and in-vivo effects of the CYP2C9*11 polymorphism on warfarin metabolism and dose
Tai, GY
Farin, F
Rieder, MJ
Dreisbach, AW
Veenstra, DL
Verlinde, CLMJ
Rettie, AE
[J]. PHARMACOGENETICS AND GENOMICS, 2005, 15 (07) : 475 - 481

← 1 →